A Multi-Center, North American, Randomized, Double-Blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART).

Trial Profile

A Multi-Center, North American, Randomized, Double-Blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART).

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Pridopidine (Primary)
  • Indications Huntington's disease
  • Focus Therapeutic Use
  • Acronyms HART
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 18 Jun 2015 Pooled safety analysis ( combination with antidepressants or antipsychotics), results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 14 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top